Praxis Precision Medicines (PRAX) Cash & Current Investments (2019 - 2026)

Praxis Precision Medicines' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $786.9 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 139.9% year-over-year to $786.9 million in Q1 2026; TTM through Mar 2026 was $786.9 million, a 139.9% increase from a year earlier, with the FY2025 full-year figure at $599.3 million, up 52.67% from the prior year.
• Cash & Current Investments rose to $786.9 million in Q1 2026 per PRAX's latest filing, from $599.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $786.9 million in Q1 2026 and bottomed at $56.0 million in Q2 2022.
• The 5-year median for Cash & Current Investments is $207.4 million (2024), against an average of $249.2 million.
• Across the five-year window, Cash & Current Investments plunged 68.14% in 2022 and surged 382.86% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $61.6 million in 2022, then jumped by 31.95% to $81.3 million in 2023, then jumped by 382.86% to $392.6 million in 2024, then jumped by 52.67% to $599.3 million in 2025, then jumped by 31.29% to $786.9 million in 2026.
• Per Business Quant, the three latest PRAX Cash & Current Investments figures stand at $786.9 million (Q1 2026), $599.3 million (Q4 2025), and $267.2 million (Q3 2025).